Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Selective tyrosine kinase inhibitor imatinib (STI571) in haematological and oncological disease].

Deutsche medizinische Wochenschrift (1946) - 1 Mar 2002

Hochhaus A

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Small Cell
Share to Clinical Trials, Phase I as Topic
Share to Clinical Trials, Phase II as Topic
Share to Cytogenetics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myelomonocytic, Chronic

Share to Mastocytosis

Share to Multicenter Studies as Topic

Share to Primary Myelofibrosis

Source

Identifiers

PMID: 11870560
DOI: 10.1055/s-2002-20427

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Selective tyrosine kinase inhibitor imatinib (STI571) in haematological and oncological disease].PMID 11870560Read ↗

[STI571: a summary of targeted therapy].Semantic proximity Read ↗

[Novel inhibitors of Bcr-Abl].Semantic proximity Read ↗

c-Abl Tyrosine Kinase and Inhibition by the Cancer Drug Imatinib (Gleevec/STI-571)Semantic proximity Read ↗

Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes backSemantic proximity Read ↗

[GIST refractory to imatinib treatment].Semantic proximity Read ↗

[Clinical Analysis for 42 Imatinib-resistant Patients with Chronic Myelogenous Leukemia].Semantic proximity Read ↗

[Sorafenib monotherapy for FLT3-ITD positive acute myeloid leukemia: a case report].Semantic proximity Read ↗

[The clinical safety and efficacy of the patients of acute myeloid leukemia with FLT3-ITD positive treated with sorafenib in combination with venetoclax and azactitidine regimen].Semantic proximity Read ↗

[Preclinical biomarker research and patient stratification of molecular target agents: the anti-angiogenic inhibitor Lenvatinib mesylate (E7080)].Semantic proximity Read ↗

[Tyrosine kinase inhibitors in the treatment of polycythemia vera and related conditions. Danish Society of Hematology].Semantic proximity Read ↗

[New therapeutic option for leukemia patients, with FLT3/Aurora kinase inhibitor, KW-2449: strategy and comparison with other kinase inhibitors].Semantic proximity Read ↗

Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.